Who doesn’t want to sleep well, lose weight, and perform in bed?
The company I’m recommending this month focuses its research on sleep, obesity, and sexual disorders. It has two drugs on the market today: Qsymia and Spedra. Qsymia is a combination of two effective weight-loss drugs. Spedra is a fast-acting treatment for erectile dysfunction.
Vivus (NASDAQ:VVUS) is the biopharmaceutical company behind Qsymia and Spedra. Their more recent drug, Qsymia, has not lived up to expectations in terms of sales. Since the height of hype for Qsymia in 2012, the company’s stock has dropped over 97%. This is a pure value play. Looking at the numbers, I feel that the stock price is approaching its bottom. It will likely drop a little more, but at under $0.80 a share, it looks like a bargain.
The official website for Vivus is www.vivus.com
I purchased a position of VVUS on August 25 for $0.95 a share and another position on October 20 for $0.79 a share. I think the stock is a good buy under $0.85 per share. I plan to hold VVUS for at least one year.
Disclaimer and disclosures: As with all investment information, you should do your own research and/or consult with a professional before making investment decisions. Remember, it’s your money. The information provided here represents my personal opinions. I own shares of VVUS.